NCT01764178View on ClinicalTrials.gov

To Evaluate the Safety and PK Characteristics in Healthy Volunteers-Livalozet

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

January 22, 2013

Primary Completion Date

March 15, 2013

Study Completion Date

December 27, 2013

Conditions
HyperlipidemiaHypertension
Interventions
DRUG

Livalo fixed combination drug

Pitavastatin 4mg / Valsartan 160mg

DRUG

Pitavastatin, Valsartan

Pitavastatin 4mg, Valsartan 160mg

Trial Locations (1)

138-736

Asan Medical Center, Seoul

Sponsors

Lead Sponsor

JW Pharmaceutical
All Listed Sponsors
lead

JW Pharmaceutical

INDUSTRY